ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

DSGN vs GYRE // EV/EBITDA & P/E VALUATION

Design Therapeutics Inc. (NASDAQ) VS. Gyre Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: DSGN 2 — GYRE 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DSGN VS. GYRE) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC DSGN GYRE SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 95.40% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -32.10% 25.40% -57.50 GYRE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 53.3x — TIE /valuation <GO>
Free Cash Flow Yield -7.88% -0.03% -7.85 GYRE /fcf-yield <GO>
Operating Margin — 9.90% — TIE /operating-margins <GO>
Net Profit Margin — 8.50% — TIE /net-margins <GO>
Revenue Growth (YoY) — 10.20% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 26.00 14.33 +11.67 DSGN /balance-sheet <GO>
Piotroski F-Score Quality 2/9 5/9 -3.00 GYRE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 42.4 29.5 +12.88 DSGN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 67.2x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $692.2M $714.8M -$22.6M GYRE /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR DSGN REV GYRE REV DSGN GROSS % GYRE GROSS % DSGN FCF GYRE FCF
FY 2025 $0 $116.6M — 95.4% -$54.6M -$180.0K
FY 2024 $0 $105.8M — 96.3% -$43.4M -$6.0M
FY 2023 $0 $113.5M — — -$58.6M $25.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DSGN // BETA —
GYRE // BETA —